Clargus homeLARGUS
Insights
Clargus Insight·SUPPLY CHAIN·Nuclear fuel, uranium·Last checked

Centrus Energy (LEU) stock and the Russian uranium ban, with most of its supply facing a 2028 cutoff

Can Centrus Energy replace Russian uranium before the US ban's waivers end?

Generated by the Published

Not investment advice.

Add Clargus as a preferred source on GoogleSee Clargus insights more often in Google Top Stories.

Card titled "America banned Russian uranium. Centrus still runs on it." More than half of the enriched uranium Centrus expects to deliver through 2027 comes from Russia's TENEX (Centrus 10-K and Q2 2026 10-Q). Timeline 2024 to 2030: Russian supply allowed only under ban waivers until January 1, 2028; Centrus's own new US capacity in Ohio from 2029; 2028 marked with no waivers and no new plant. Stock down 73% since January 28, against Oklo down 77%, NuScale down 75% and the S&P 500 up 11%. Backlog $7.0 billion, of which $5.4 billion depends on building new capacity.

The insight

Centrus Energy ($LEU), the US uranium enrichment company, was bought as America's answer to the Russian uranium ban. Its own filings say "well over one-half" of the enriched uranium it expects to deliver through 2027 comes from Russia's TENEX. The ban's waivers end on January 1, 2028. Its first new US capacity is due in 2029.

Why the stock fell: mostly the nuclear trade unwinding. Since January 28, Centrus is down 73%, Oklo 77%, NuScale 75%, Cameco 47%, while the S&P 500 rose 11%. The Centrus-specific hits:
- February 11: fourth-quarter earnings missed and 2026 revenue guidance came in flat ($425 to $475 million). The stock fell 21%, then 12% the next day.
- April to August: the Energy Department dropped funding to run its HALEU cascade, about $0.8 billion of backlog.
- September: a $500 million raise, mostly in pre-funded warrants.

Workarounds: limited. The waiver deadline is in the law, so going past it needs Congress. Centrus says its other suppliers, Orano the largest, "are not sufficient to replace" TENEX. There is no re-export exception. The LEU business at risk was 77% of 2025 revenue.

What's priced: LEU closed at $92.58 on Nov 4, a 52-week low, about $1.9 billion in market value, with $2.24 billion of cash.

Clargus's read: the market has already marked Centrus down with the nuclear group. The part it may not have priced is 2028, a year with no Russian waivers and no new plant, which the Q3 release does not address.

Inflection points to watch:
- Piketon site lease (expires October 2027): the Energy Department aims to extend it before December 31.
- Investor Day in December: any plan for 2028 supply.
- $5.4 billion of contingent backlog turning into firm orders.

What would challenge this: a 2028 supply contract, a law extending waivers, or capacity pulled into 2028.

What is the evidence?

"Through 2027, well over one-half of the LEU that we expect to deliver to customers was sourced under the TENEX Supply Contract." Other sources "are not sufficient to replace the TENEX supply."2026-06-30Centrus Energy 10-K for 2025 and Q2 2026 10-Q (SEC)Company filingVerified
Waivers "shall terminate not later than January 1, 2028"2024-05-13Prohibiting Russian Uranium Imports Act, Public Law 118-62Regulatory recordVerified
First new centrifuge capacity expected to come online in Ohio in 20292026-10-29Centrus first centrifuge release (SEC 8-K)Company releaseVerified
Backlog of $7.0 billion, including about $5.4 billion of contingent sales commitments tied to building capacity at Piketon; Q3 revenue $55.5 million, adjusted net loss $9.4 million
$7.0B; $5.4B contingent
2026-09-30Centrus Q3 2026 results (SEC 8-K)Company releaseVerified
Q4 2025 results and 2026 revenue guidance of $425 to $475 million, against 2025 revenue of $448.7 million2026-02-10Centrus Q4 2025 results (SEC 8-K)Company releaseVerified
DOE budget for fiscal 2027 includes no further funding to operate the HALEU cascade; DOE does not intend to exercise further options under that contract (about $0.8 billion of backlog)
~$0.8B
2026-06-30Centrus Q1 and Q2 2026 10-Q (SEC)Company filingVerified
LEU segment share of 2025 revenue
$346.2M of $448.7M, 77%
2025-12-31Centrus 10-K for 2025 (SEC)Company filingVerified
Piketon lease expires October 1, 2027; DOE aims to extend it before December 31, 20262026-11-02Centrus S-3ASR (SEC)Company filingVerified
$500 million offering, mostly pre-funded warrants, priced at $199.642026-09-09Centrus prospectus supplement (SEC 424B5)Company filingVerified
Price change from January 28 to November 4 for Centrus and peers
LEU -73%, Oklo -77%, NuScale -75%, Cameco -47%, S&P 500 +11%
2026-11-04Clargus end-of-day price dataClargus market dataClargus data
Worst Centrus days compared with peers on the same day: February 11 (-20.7%, peers flat) and January 8 (-11.4%, peers flat) were company-specific; most other large drops matched the nuclear group2026-11-04Clargus end-of-day price dataClargus market dataClargus data
Centrus linked to HALEU supply, the Russian import ban and the Ohio restart in 108 news mentions over 30 days
108 mentions
2026-11-05Clargus knowledge graphClargus graphClargus data

How are the companies connected?

Centrus between the Russian supply it resells and the US capacity it is building.

  1. TENEX (Russia)supplies well over half, through 2027 →Centrus LEU deliveries
  2. Russian uranium import banwaivers end →TENEX (Russia)2028-01-01
  3. Energy DepartmentPiketon lease extension pending →Ohio centrifuge capacity (2029)2026-12-31
  4. Ohio centrifuge capacity (2029)replaces Russian supply from →Centrus LEU deliveries2029
  5. Nuclear stocks (Oklo, NuScale)moved together in 2026 →Centrus LEU deliveries

What does it mean for investors?

The thesis

The market has marked Centrus down with the nuclear group. The part it may not have priced is 2028, a year with no Russian waivers and no new plant, which the Q3 release does not address.

The case against

Centrus has $2.24 billion of cash, the only US-made advanced centrifuges, and a $5.4 billion contingent backlog; Congress or new supply contracts could close the 2028 gap.

Open questions

  • The Energy Department decision on the pending waiver for 2026 and 2027 sales
  • Whether management outlines a 2028 supply plan
  • Russian export licenses for each TENEX shipment

What to monitor

  • Piketon site lease extension (2026-12-31)
  • Centrus Investor Day (2026-12)
  • Q4 2026 results (2027-02)
  • Waiver sunset (2028-01-01)

What would prove this wrong?

A 2028 supply contract, a law extending the waivers, or new capacity pulled into 2028.

How was this insight made?

Data examined

  • Clargus knowledge graph: Centrus, HALEU and Russian uranium ban relationships, 2026-10-06 to 2026-11-05
  • Primary sources checked 2026-11-05: Centrus 10-K, 10-Qs, 8-Ks, S-3ASR and 424B5; Public Law 118-62
  • Clargus end-of-day price data for Centrus, Oklo, NuScale, Cameco, BWXT, the URA ETF and the S&P 500

Approach

The graph linked Centrus to HALEU supply and the Russian ban. Its filings were read for supply sources, deadlines and backlog. The drawdown was split into sector and company-specific moves by comparing each large down day with peers on the same day.

Limits

The Q3 2026 10-Q and the Q3 call transcript were not available when checked; management may have addressed 2028 on the call. The causes of single-day moves are matched to dated disclosures and are not proven.

Last checked:

© 2026 Clargus. All rights reserved. You may quote a short excerpt with a link to this page. Do not republish the full text, charts or images without written permission.

Add Clargus as a preferred source on GoogleSee Clargus insights more often in Google Top Stories.

Run this on your own names.

Each post started from an event in the graph, not a screen. In the beta, the same agents keep researching the names you hold and flag the next event in the chain.

Centrus EnergyRussian uranium banHALEUNuclear fuel

No sales call.

Join Waitlist for your desk or your team →